BWPT-301: FDA approved an expanded Phase II open-label, dose-escalating trial of BWPT-301 in children with AIDS between the ages of one and 12. The company has

Biomune Systems Inc. (BIME), Salt Lake City Product: BWPT-301 (Immuno-C) Indication: Cryptosporidiosis Status: FDA approved an expanded Phase II open-label, dose-escalating trial of BWPT-301 in childr...